New Amsterdam Pharma
Marc Ditmarsch joined NewAmsterdam Pharma as of January 2020 as VP Clinical & Operations.
Marc followed his medical training at the Free University in Amsterdam in the Netherlands practiced in vascular surgery and accident and emergency medicine for 6 years. He has more than 20 years of professional experience in the pharmaceutical industry where he started as medical advisor for the atherothrombosis business unit of Sanofi-Synthelabo. In 2004 Marc joined AstraZeneca as a global research phycisian for cardiovascular development department and was engaged in the CRESTOR clinical development program.
Marc moved to Roche in 2008 where he lead the phase 3b development program for the CETP inhibitor including the initiation and execution of the 2nd Cardiovascular Outcomes study. In 2014 Marc joined AstraZeneca as a Global Product Vice President in the Global Medicines Development organisation where he was responsible for the BRILINTA clinical development program which included 6 Cardiovascular outcomes trials in more than 80.000 patients. In 2016 He joined the Dutch marketing company of AstraZeneca as the Medical Director. During his career in the pharmaceutical industry Marc has published various articles in peer reviewed journals.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.